Abuse liability of centrally acting non-opioid analgesics and muscle relaxants - A brief update based on a comparison of pharmacovigilance data and evidence from the literature

International Journal of Neuropsychopharmacology

Volumn 17, Issue 6, 2014, Pages 957-959

  Gahr, Maximilian ^a   Freudenmann, Roland W ^a   Eller, Jonas ^a   Schönfeldt Lecuona, Carlos ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Addiction; Diversion; Drug safety; Pain management; Pharmacovigilance

Indexed keywords

ANALGESIC AGENT; BACLOFEN; CLONIDINE; DIPYRONE; KETAMINE; METHOCARBAMOL; MUSCLE RELAXANT AGENT; OMEGA CONOTOXIN MVIIA; ORPHENADRINE; PARACETAMOL; PHENAZONE; PRIDINOL; PROPYPHENAZONE; TIZANIDINE; TOLPERISONE; CENTRAL MUSCLE RELAXANT; CENTRAL NERVOUS SYSTEM AGENTS;

ANALGESIC AGENT ABUSE; ARTICLE; DRUG DATABASE; DRUG SURVEILLANCE PROGRAM; GERMANY; HUMAN; PAIN; PRIORITY JOURNAL; ADOLESCENT; ADULT; AGED; COMPARATIVE STUDY; EPIDEMIOLOGY; FEMALE; MALE; MIDDLE AGED; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANALGESICS, NON-NARCOTIC; CENTRAL NERVOUS SYSTEM AGENTS; DATABASES, PHARMACEUTICAL; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; MUSCLE RELAXANTS, CENTRAL; PHARMACOVIGILANCE; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 84899953457     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713001600     Document Type: Article

References (20)

1. Abbott F, Hellemans K. (2000) Phenacetin, acetaminophen and dipyrone: Analgesics and rewarding effects. Behav Brain Res 112:177-186.
2. Ahmed S, Petchkovsky L. (1980) Abuse of ketamine. Br J Psychiatry 137:303.
3. Barker JJ, de Carle D, Anuras S. (1977) Chronic excessive acetaminophen use and liver damage. Ann Intern Med 87:299-301.
4. Blakley B, Schilling H. (2008) Deafness associated with acetaminophen and codein abuse. J Otolaryngol Head Neck Surg 37:507-509.
5. Colás Chacartequi R, Temprano González R, Gómez Arruza C, Munoz Cacho P, Pascual Gómez J. (2005) Abuse patterns of analgesics in chronic daily headache: A study in the general population. Rev Clin Esp 205:583-587.
6. Critchlow D. (2006) A case of ketamine dependence with discontinuation symptoms. Addiction 101:1212-1213.
7. Dennison S. (2001) Clonidine abuse among opiate addicts. Psychiatr Q 72:191-195.
8. Dy E, Yates W. (1996) Atypical drug abuse: A case report involving clonidine. Am Fam Physician 54:1035-1038.
9. Hayes B, Balster R. (1989) Assessment of the abuse potential of methocarbamol in primates. NIDA Res Monogr 95:1
10. Mugglestone C. (1985) Dangers of orphenadrine in psychiatric patients. Lancet 2:617.
11. Nakra B, Lee F, Gaind R. (1973) Risk of paracetamol abuse. Lancet 2:451-452.
12. Nasti J, Brakoulias V. (2011) Chronic baclofen abuse and withdrawal delirium. Aust N Z J Psychiatry 45:86-87.
13. Preston K, Guarino J, Kirk W, Griffiths R. (1989) Evaluation of the abuse potential of methocarbamol. J Pharmacol Exp Ther 248:1146-1157.
14. Preston K, Wolf B, Guarino J, Griffiths R. (1992) Subjective and behavioral effects of diphenhydramine, lorazepam and methocarbamol: Evaluation of abuse liability. J Pharmacol Exp Ther 262:707-720.
15. Sannerud C, Ator N, Griffiths R. (1991) Methocarbamol: Evaluation of reinforcing and discriminative stimulus effects. Behav Pharmacol 2:143-150.
16. Schaut J, Schnoll S. (1983) Four cases of clonidine abuse. Am J Psychiatry 140:1625-1627.
17. Schifano F, Marra R, Magni G. (1988) Orphenadrine abuse. South Med J 81:546-547.
18. Schindler E, Tirado-Morales D, Kushon D. (2013) Clonidine abuse in a methadone-maintained, clonazepam-Abusing patient. J Addict Med 7:218-219.
19. Shariatmadari M. (1975) Letter: Orphenadrine dependence. Br Med J 3:486.
20. Zullino D, Eskenasy A, Beeson J. (2003) High-dose tizanidine abuse. Psychopharmacol Bull 37:5-6.